Matthew W. Foehr - Nov 11, 2021 Form 4 Insider Report for LIGAND PHARMACEUTICALS INC (LGND)

Role
President and COO
Signature
By: Charles S. Berkman For: Matthew W. Foehr
Stock symbol
LGND
Transactions as of
Nov 11, 2021
Transactions value $
-$1,471,437
Form type
4
Date filed
11/12/2021, 03:54 PM
Previous filing
Aug 5, 2021
Next filing
Jan 5, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction LGND Common Stock Options Exercise $103K +1.03K +0.62% $100.38 167K Nov 11, 2021 Direct
transaction LGND Common Stock Options Exercise $245K +11.2K +6.7% $21.92 178K Nov 11, 2021 Direct
transaction LGND Common Stock Sale -$1.82M -11.2K -6.28% $163.02 167K Nov 11, 2021 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction LGND Employee Stock Option (right to buy) Options Exercise $0 -11.2K -100% $0.00* 0 Nov 11, 2021 Common Stock 11.2K $21.92 Direct F2
transaction LGND Employee Stock Option (right to buy) Options Exercise $0 -1.03K -4.05% $0.00 24.3K Nov 11, 2021 Common Stock 1.03K $100.38 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $161.41 to $166.38, inclusive. The reporting person undertakes to provide, upon request to the Securities Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F2 Grant to reporting person of options, exercisable over a 4-year period measured from the date of grant, 12-1/2% after six months, then 1/48th of the Option Shares per month thereafter. The date of grant was 02/15/13.
F3 Grant to reporting person of options to purchase shares of common stock ("Option Shares"), exercisable over a 4-year period measured from the date of grant, 12-1/2% after six months, then 1/48th of the Option Shares per month thereafter. The date of grant was 02/24/2017.